Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle
about
Infections in myelodysplastic syndromesAntifungal Therapy in Hematopoietic Stem Cell Transplant RecipientsInvasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients.Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropeniaDiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsBreakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.Method for measuring postantifungal effect in Aspergillus species.2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.Canadian clinical practice guidelines for invasive candidiasis in adults.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.Caspofungin acetate for treatment of invasive fungal infections.Itraconazole--perspectives for the management of invasive aspergillosis.Fungal infections in renal transplant patients.Systemic antifungal therapy: new options, new challenges.New and emerging antifungal agents: impact on respiratory infections.Management of infectious complications in the hematopoietic stem cell transplant recipient.Changing strategies for the management of invasive fungal infections.Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approachRecent advances in antifungal pharmacotherapy for invasive fungal infections.New developments in antifungal strategy.Therapy of systemic fungal infections.A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis.Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysisEfficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.Fungal pneumonia due to molds in patients with hematological malignancies.Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.Antifungal management in cancer patients.Considerations in the approach to invasive fungal infection in patients with haematological malignancies.Current and future therapeutic options in the management of invasive aspergillosis.Current options in antifungal pharmacotherapy.Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia.Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in KoreaIntravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever.
P2860
Q26859275-671D60D2-6D7D-457B-B8B9-1352DB308551Q28080147-92756875-10AF-436C-8FDC-AD8C33BEC9D8Q33234912-FD19005A-3887-4832-9093-F5FF8F3E0452Q33265510-E16A68DD-23B2-42F9-9049-6182DA7B4F56Q33753500-DA3A4E79-109D-4C47-B4A1-6D9C6276496AQ33876645-C91A41DE-881F-43A2-B181-E6F62FC96B2DQ34041745-1669B1CD-7648-47EB-A393-185DCA65D389Q34073422-5631F5C1-E316-45DF-8D5E-345F1A37D886Q34108018-ACDF05D4-2F9B-44DA-9304-6DAFE7765C76Q34114674-FAC5977D-F589-43B0-A62A-FCDCCCBF3E28Q34237335-61D36E12-3D5F-4AAE-899B-2EF638014D49Q34532546-EDD841D2-C25F-4DF3-B79F-030DF688C0FDQ34546811-B1FFD9B1-D997-4679-8BD2-1E2D1665EF3DQ35033597-60317E51-92EF-414A-ACDC-70B98254AC67Q35035091-ABC57244-677F-457E-8B95-77B587355C24Q35105394-32EBA904-F8A9-475D-9CE6-080767C5772CQ35387111-86706040-7DB2-4BCF-9429-6F7401511466Q35585219-5CD5AB9B-D4A9-40EC-92A9-285808D2B441Q35627629-5AFA2AAC-709B-463D-837E-AF08B7B7BEEBQ35675979-6CA59A5E-ABDB-44E6-8D1F-27C65842CA59Q35678997-C27B6DE6-ECA1-48AB-8035-F1E76AD22CF3Q35794490-E873D402-5F2F-4416-A585-C0398201597AQ35917383-C974D89A-D41C-426D-9D8A-0568E2C9A111Q35917388-7CF24E32-5909-4F23-8B95-2DA71B015B4EQ35967453-21A8AC34-3253-4CF8-9DC2-7AD7565AF6C5Q35987403-39671C1C-FE12-4F1A-A8FB-EF2268CF9A1EQ36042366-0A617C80-F115-4766-9D28-FD6E737274CFQ36285521-A8EA7924-439D-4334-9166-3FA23F26438FQ36456366-404F892F-6C49-43D9-B122-348B6C45A000Q36613885-AF39C898-FF37-4E14-AE9D-C3F52A39E733Q36616182-1A05E703-EA6D-41BB-82DD-EDCE1FE5657AQ36895540-FD577291-E4C7-4E25-B8A5-BAC4134B0D9AQ37009912-6DE8BECE-9AD5-4FBD-B56E-E20944C35CCFQ37049537-3CA66360-CBE8-4C1B-890B-5BBED59FB926Q37079099-2814B053-F153-4AD2-9EEF-FF974DBDA5A0Q37151326-E29778BC-E6BF-4AE2-86BB-8E21178B98F7Q37263911-84E0420D-A576-42DA-AB14-9EA7B5DC056DQ37418841-1279C79C-03B9-436B-996F-686BCE1B4ED8Q37473671-F11919A2-14F2-4EAF-BD5A-985296246BA2Q37474433-649891B7-8F4E-4115-BE5D-C0FB1C154AC6
P2860
Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Intravenous and oral itraconaz ...... erapy. A randomized, controlle
@en
type
label
Intravenous and oral itraconaz ...... erapy. A randomized, controlle
@en
prefLabel
Intravenous and oral itraconaz ...... erapy. A randomized, controlle
@en
P2093
P1476
Intravenous and oral itraconaz ...... erapy. A randomized, controlle
@en
P2093
A C Reboli
A P Schwarer
D J Winston
E Chwetzoff
Itraconazole Neutropenia Study Group
K De Beule
M Boogaerts
P304
P356
10.7326/0003-4819-135-6-200109180-00010
P407
P577
2001-09-01T00:00:00Z